Device type · KTO
Reagent, Immunoassay, Igg
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
KTO
Immunology
Device class
Class I
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Reagent, Immunoassay, Igg
- Product code
- KTO
- Device class
- Class I
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5530
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for KTO
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1448-2015 · Started Dec 22, 2014 · Posted by FDA Apr 15, 2015
Reason given: The firm is recalling three batches (FP14A09, FP14A10, FP14A11) of SpermMAR IgA test due to new formulation causing the motility of sperm cells to reduce in certain samples when the new bead solution was added.
Cause as FDA categorized it: Component design/selection
Z-0928-03 · Started May 7, 2003 · Posted by FDA Jun 17, 2003
Reason given: Kit does not stain tissues properly.
Cause as FDA categorized it: Other
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.